First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia

Journal of Clinical Microbiology

Volumn 48, Issue 6, 2010, Pages 2199-2204

  Al Obeid, S ^a   Haddad, Q ^a   Cherkaoui, A ^b   Schrenzel, J ^b   Francois P ^b  

^a SECURITY FORCES HOSPITAL   (Saudi Arabia)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; LYSOSTAPHIN; MEROPENEM; METICILLIN; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; AGED; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BACTERIUM DETECTION; BACTERIUM ISOLATE; BLOOD CULTURE; BRAIN HEMORRHAGE; CASE REPORT; CHEMICAL STRUCTURE; CHROMOSOME; DRUG SENSITIVITY; DRUG SUBSTITUTION; FEVER; GENOTYPE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SAUDI ARABIA; SEPSIS; STAPHYLOCOCCUS AUREUS; SYSTOLIC DYSFUNCTION; TREATMENT DURATION; TREATMENT FAILURE;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; BLOOD; CHROMOSOMES, BACTERIAL; CLUSTER ANALYSIS; DNA FINGERPRINTING; DNA, BACTERIAL; GENES, BACTERIAL; GENOTYPE; HUMANS; LYSOSTAPHIN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROARRAY ANALYSIS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PLASMIDS; SAUDI ARABIA; SEPSIS; SERUM; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 77952938715     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00954-09     Document Type: Article

References (65)

1. Al-Mustafa, Z. H., and M. S. Al-Ghamdi. 2002. Use of antibiotics in the poultry industry in Saudi Arabia: implications for public health. Ann. Saudi Med. 22:4-7.
2. Andrade-Baiocchi, S., M. C. Tognim, O. C. Baiocchi, and H. S. Sader. 2003. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn. Microbiol. Infect. Dis. 45:149-152.
3. Appelbaum, P. C. 2006. MRSA - the tip of the iceberg. Clin. Microbiol. Infect. 12(Suppl. 2):3-10.
4. Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, J. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588.
5. Baddour, M. M., M. M. AbuElKheir, and A. J. Fatani. 2006. Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia. Ann. Clin. Microbiol. Antimicrob. 5:30.
6. Baddour, M. M., M. M. AbuElKheir, A. J. Fatani, M. F. Bohol, and M. N. Al Ahdal. 2007. Molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) isolates from major hospitals in Riyadh, Saudi Arabia. Can. J. Microbiol. 53:931-936.
7. Bayer, A. S. 1993. Infective endocarditis. Clin. Infect. Dis. 17:313-320.
8. Borg, M. A., R. Zerafa, D. Morrison, and P. Cuschieri. 2005. Incidence of glycopeptide hetero-intermediate Staphylococcus aureus strains in Maltese hospitals. Clin. Microbiol. Infect. 11:405-407.
9. Boyle-Vavra, S., M. Challapalli, and R. S. Daum. 2003. Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 47:2036-2039.
10. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
11. Charbonnier, Y., B. M. Gettler, P. Francois, M. Bento, A. Renzoni, P. Vaudaux, W. Schlegel, and J. Schrenzel. 2005. A generic approach for the design of whole-genome oligoarrays, validated for genomotyping, deletion mapping and gene expression analysis on Staphylococcus aureus. BMC Genomics 6:95.
12. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing: 15th informational supplement M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, C. G. Gemmell, M. N. Kim, M. C. Ploy, N. El Solh, V. Ferraz, and K. Hiramatsu. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14.
15. EARSS. 2005. European Antimicrobial Resistance Surveillance System (EARSS) annual report 2004. EARSS, Bilthoven, Netherlands.
16. Enright, M. C., N. P. Day, C. E. Davies, S. J. Peacock, and B. G. Spratt. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015. (Pubitemid 30140551)
17. Feil, E. J., E. K. Nickerson, N. Chantratita, V. Wuthiekanun, P. Srisomang, R. Cousins, W. Pan, G. Zhang, B. Xu, N. P. Day, and S. J. Peacock. 2008. Rapid detection of the pandemic methicillin-resistant Staphylococcus aureus clone ST 239, a dominant strain in Asian hospitals. J. Clin. Microbiol. 46:1520-1522.
18. Ferry, T., D. Thomas, A. L. Genestier, M. Bes, G. Lina, F. Vandenesch, and J. Etienne. 2005. Comparative prevalence of superantigen genes in Staphylococcus aureus isolates causing sepsis with and without septic shock. Clin. Infect. Dis. 41:771-777.
19. Francois, P., S. Harbarth, A. Huyghe, G. Renzi, M. Bento, A. Gervaix, D. Pittet, and J. Schrenzel. 2008. Methicillin-resistant Staphylococcus aureus, Geneva, Switzerland, 1993-2005. Emerg. Infect. Dis. 14:304-307.
20. Francois, P., A. Huyghe, Y. Charbonnier, M. Bento, S. Herzig, I. Topolski, B. Fleury, D. Lew, P. Vaudaux, S. Harbarth, W. Van Leeuwen, A. Van Belkum, D. S. Blanc, D. Pittet, and J. Schrenzel. 2005. Use of an automated multiple-locus, variable-number tandem repeat-based method for rapid and high-throughput genotyping of Staphylococcus aureus isolates. J. Clin. Microbiol. 43:3346-3355.
21. Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, and F. C. Tenover. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36:429-439.
22. Garnier, F., D. Chainier, T. Walsh, A. Karlsson, A. Bolmstrom, C. Grelaud, M. Mounier, F. Denis, and M. C. Ploy. 2006. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J. Antimicrob. Chemother. 57:146-149.
23. Geisel, R., F. J. Schmitz, A. C. Fluit, and H. Labischinski. 2001. Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis. 20:685-697. (Pubitemid 33020779)
24. Hiramatsu, K. 1998. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. 104:7S-10S.
25. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
26. Howden, B. P., T. P. Stinear, D. L. Allen, P. D. R. Johnson, P. B. Ward, and J. K. Davies. 2008. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3755-3762.
27. Howden, B. P., P. B. Ward, P. G. Charles, T. M. Korman, A. Fuller, P. du Cros, E. A. Grabsch, S. A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P. D. Johnson, A. J. Morris, B. C. Mayall, and M. L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
28. Howe, R. A., A. Monk, M. Wootton, T. R. Walsh, and M. C. Enright. 2004. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg. Infect. Dis. 10:855-857.
29. Hubert, S. K., J. M. Mohammed, S. K. Fridkin, R. P. Gaynes, J. E. McGowan, Jr., and F. C. Tenover. 1999. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J. Clin. Microbiol. 37:3590-3593.
30. Ike, Y., Y. Arakawa, X. Ma, K. Tatewaki, M. Nagasawa, H. Tomita, K. Tanimoto, and S. Fujimoto. 2001. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J. Clin. Microbiol. 39:4445-4451.
31. Kim, M. N., C. H. Pai, J. H. Woo, J. S. Ryu, and K. Hiramatsu. 2000. Vancomycin-intermediate Staphylococcus aureus in Korea. J. Clin. Microbiol. 38:3879-3881.
32. Koessler, T., P. Francois, Y. Charbonnier, A. Huyghe, M. Bento, S. Dharan, G. Renzi, D. Lew, S. Harbarth, D. Pittet, and J. Schrenzel. 2006. Use of oligoarrays for characterization of community-onset methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 44:1040-1048.
33. Kosowska-Shick, K., L. M. Ednie, P. McGhee, K. Smith, C. D. Todd, A. Wehler, and P. C. Appelbaum. 2008. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center. Antimicrob. Agents Chemother. 52:4510-4513.
34. Kuroda, M., T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya, C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu. 2001. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357:1225-1240.
35. Liu, C., and H. F. Chambers. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47:3040-3045.
36. Maki, H., N. McCallum, M. Bischoff, A. Wada, and B. Berger-Bachi. 2004. tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 48:1953-1959.
37. McAleese, F., S. W. Wu, K. Sieradzki, P. Dunman, E. Murphy, S. Projan, and A. Tomasz. 2006. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin. J. Bacteriol. 188:1120-1133.
38. Miller, D., L. F. Urdaneta, and A. Weltman. 2002. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb. Mortal. Wkly. Rep. 51:902.
39. Moise, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2002. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J. Antimicrob. Chemother. 50:1017-1026.
40. Moise, P. A., and J. J. Schentag. 2000. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int. J. Antimicrob. Agents 16(Suppl. 1):S31-S34.
41. Mwangi, M. M., S. W. Wu, Y. Zhou, K. Sieradzki, H. de Lencastre, P. Richardson, D. Bruce, E. Rubin, E. Myers, E. D. Siggia, and A. Tomasz. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U. S. A. 104:9451-9456.
42. Noskin, G. A., R. J. Rubin, J. J. Schentag, J. Kluytmans, E. C. Hedblom, C. Jacobson, M. Smulders, E. Gemmen, and M. Bharmal. 2007. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). Clin. Infect. Dis. 45:1132-1140.
43. Ploy, M. C., C. Grelaud, C. Martin, L. de Lumley, and F. Denis. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.
44. Rahal, J. J., Jr., Y. K. Chan, and G. Johnson. 1986. Relationship of staphylococcal tolerance, teichoic acid antibody, and serum bactericidal activity to therapeutic outcome in Staphylococcus aureus bacteremia. Am. J. Med. 81:43-52.
45. Reis, A. G., A. P. Eisencraft, B. Ejzenberg, E. R. Baldacci, M. S. Kodaira, P. P. Domingues, S. J. Grisi, Y. Okay, and C. Mendes. 1995. Staphylococcus aureus septicemia in children: bacterial tolerance to vancomycin and serum bactericidal activity. Rev. Assoc. Med. Bras. 41:47-52. (In Portuguese.)
46. Rolain, J. M., P. Francois, D. Hernandez, F. Bittar, H. Richet, G. Fournous, Y. Mattenberger, E. Bosdure, N. Stremler, J. C. Dubus, J. Sarles, M. Reynaud-Gaubert, S. Boniface, J. Schrenzel, and D. Raoult. 2009. Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage. Biol. Direct 4:1.
47. Rybak, M. J., S. N. Leonard, K. L. Rossi, C. M. Cheung, H. S. Sader, and R. N. Jones. 2008. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950-2954.
48. Sakoulas, G., G. M. Eliopoulos, V. G. Fowler, Jr., R. C. Moellering, Jr., R. P. Novick, N. Lucindo, M. R. Yeaman, and A. S. Bayer. 2005. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob. Agents Chemother. 49:2687-2692.
49. Sakoulas, G., H. S. Gold, R. A. Cohen, L. Venkataraman, R. C. Moellering, and G. M. Eliopoulos. 2006. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J. Antimicrob. Chemother. 57:699-704.
50. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
51. Scherl, A., P. Francois, Y. Charbonnier, J. M. Deshusses, T. Koessler, A. Huyghe, M. Bento, J. Stahl-Zeng, A. Fischer, A. Masselot, F. Gallé, A. Renzoni, P. Vaudaux, D. Lew, C. G. Zimmermann-Ivol, P. A. Binz, J. C. Sanchez, D. F. Hochstrasser, and J. Schrenzel. 2006. Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers. BMC Genomics 7:296.
52. Sievert, D. M., J. T. Rudrik, J. B. Patel, L. C. McDonald, M. J. Wilkins, and J. C. Hageman. 2008. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46:668-674.
53. Stefani, S., and P. E. Varaldo. 2003. Epidemiology of methicillin-resistant staphylococci in Europe. Clin. Microbiol. Infect. 9:1179-1186.
54. Sun, W., H. Chen, Y. Liu, C. Zhao, W. W. Nichols, M. Chen, J. Zhang, Y. Ma, and H. Wang. 2009. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrob. Agents Chemother. 53:3642-3649.
55. Tenover, F. C., and R. C. Moellering, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215.
56. Trakulsomboon, S., S. Danchaivijitr, Y. Rongrungruang, C. Dhiraputra, W. Susaemgrat, T. Ito, and K. Hiramatsu. 2001. First report of methicillin- resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J. Clin. Microbiol. 39:591-595.
57. Tristan, A., T. Ferry, G. Durand, O. Dauwalder, M. Bes, G. Lina, F. Vandenesch, and J. Etienne. 2007. Virulence determinants in community and hospital meticillin-resistant Staphylococcus aureus. J. Hosp. Infect. 65(Suppl. 2):105-109.
58. Vaudaux, P., P. Francois, B. Berger-Bachi, and D. P. Lew. 2001. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J. Antimicrob. Chemother. 47:163-170. (Pubitemid 32149521)
59. Wang, G., J. F. Hindler, K. W. Ward, and D. A. Bruckner. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886.
60. Ward, P. B., P. D. Johnson, E. A. Grabsch, B. C. Mayall, and M. L. Grayson. 2001. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med. J. Aust. 175:480-483.
61. Weigel, L. M., D. B. Clewell, S. R. Gill, N. C. Clark, L. K. McDougal, S. E. Flannagan, J. F. Kolonay, J. Shetty, G. E. Killgore, and F. C. Tenover. 2003. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302:1569-1571.
62. Wisplinghoff, H., B. Ewertz, S. Wisplinghoff, D. Stefanik, G. Plum, F. Perdreau-Remington, and H. Seifert. 2005. Molecular evolution of methicillin-resistant Staphylococcus aureus in the metropolitan area of Cologne, Germany, from 1984 to 1998. J. Clin. Microbiol. 43:5445-5451.
63. Woodford, N., M. Warner, and H. M. Aucken. 2000. Vancomycin resistance among epidemic strains of methicillin-resistant Staphylococcus aureus in England and Wales. J. Antimicrob. Chemother. 45:258-259.
64. Woods, C. W., A. C. Cheng, V. G. Fowler, Jr., M. Moorefield, J. Frederick, G. Sakoulas, V. G. Meka, F. C. Tenover, P. Zwadyk, and K. H. Wilson. 2004. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 38:1188-1191.
65. Wootton, M., A. P. MacGowan, T. R. Walsh, and R. A. Howe. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329-332.